NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of RxSight, Inc. (NASDAQ: RXST)?Did you purchase your shares between November 7, 2024 and July 8, 2025, inclusive?Did you lose money in you ...

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2][3]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline of October 21, 2025, to apply as Lead Plaintiff if they purchased C3 securities during the Class Period [3]. - The lawsuit follows C3's announcement of disappointing preliminary financial results for Q1 of fiscal 2026 and a reduction in revenue guidance for the full fiscal year 2026, attributed to a reorganization with new leadership and health issues of the CEO [3]. Group 2: Stock Market Reaction - Following the negative news, C3's stock price dropped by $5.66 per share, representing a decline of 25.58%, closing at $16.47 per share on August 11, 2025 [4].

Core Viewpoint - The Snap Inc. class action lawsuit alleges that the company and its executives misled investors regarding advertising revenue and growth expectations, leading to significant financial losses for shareholders during the specified class period [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Abdul-Hameed v. Snap Inc., No. 25-cv-07844 (C.D. Cal.), and it involves purchasers of Snap securities from April 29, 2025, to August 5, 2025 [1]. - Investors have until October 20, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Snap's executives created a false impression of reliable advertising revenue information while downplaying macroeconomic instability [3]. Group 2: Allegations Against Snap - The lawsuit alleges that Snap's optimistic reports on advertising growth were misleading and did not reflect the company's actual performance, which was impacted by execution errors [3]. - On August 5, 2025, Snap reported disappointing second-quarter results, revealing a significant deceleration in advertising revenue, which caused the stock price to drop over 17% [4]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Snap securities during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can choose a law firm to litigate the case [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Innovative Solutions and Support, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - On August 14, 2025, IS&S announced its fiscal third quarter financial results, indicating a "pull-forward of F-16 production" which is expected to impact revenue over the next two quarters [2] - Following the announcement, IS&S's stock price dropped by $6.22 per share, or 31.53%, closing at $13.51 per share on the same day [2] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2] Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2] - It is alleged that the defendants overstated the demand for RxSight's products [2] - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2] - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - A class action securities lawsuit has been filed against XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, alleging securities fraud that affected investors between September 27, 2023, and January 27, 2025 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover losses for investors of XPLR Infrastructure, LP who were negatively impacted by alleged securities fraud during the specified period [2]. Case Details - The complaint claims that the defendants made false statements and concealed critical information, including: - XPLR was facing challenges in maintaining its operations as a yieldco [3]. - Defendants temporarily addressed these issues through certain financing arrangements while downplaying associated risks [3]. - XPLR could not resolve these financings before their maturity without risking significant unitholder dilution [3]. - Defendants planned to stop cash distributions to investors to redirect funds to resolve these financings [3]. - The yieldco business model and distribution growth rate of XPLR were unsustainable [3]. - Public statements made by the defendants were materially false and misleading throughout the relevant time [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until September 8, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the proposed buyout of Dayforce Inc. by Thoma Bravo at a price of $70.00 per share, amid concerns that shareholders may not be receiving adequate compensation for their shares [1][2][3]. Group 1: Buyout Details - On August 21, 2025, Dayforce announced its agreement to be acquired by private equity firm Thoma Bravo for $70.00 per share in cash [2]. - Following the transaction's closure, Dayforce shareholders will be cashed out and the company's shares will cease to be publicly traded [2]. Group 2: Investigation Focus - The investigation aims to assess whether Dayforce investors are receiving sufficient monetary consideration for their shares [3]. - There are concerns regarding potential breaches of fiduciary duties or violations of securities laws by the company's officers and/or directors in agreeing to the buyout price [3]. - Analysts had set price targets for Dayforce's shares exceeding $80.00 per share at the time of the announcement, raising questions about the fairness of the buyout price [3].

Core Viewpoint - A class action lawsuit has been filed against Lockheed Martin Corporation, alleging violations of the Securities Exchange Act of 1934 due to misleading statements and lack of effective internal controls, resulting in significant financial losses for the company and its investors [1][3]. Group 1: Allegations and Financial Impact - The lawsuit claims that Lockheed Martin made false statements regarding its internal controls and ability to meet contract commitments, which led to an overstatement of its financial health [3]. - On October 22, 2024, Lockheed Martin announced an $80 million loss on a classified program, causing its stock price to drop over 6% [4]. - On January 28, 2025, the company reported pre-tax losses of $1.7 billion related to classified programs, leading to a more than 9% decline in stock price [5]. - On July 22, 2025, Lockheed Martin disclosed an additional $1.6 billion in pre-tax losses, including $950 million from its Aeronautics Classified program, resulting in a nearly 11% drop in stock price [6]. Group 2: Class Action Details - Investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025, can seek to be appointed as lead plaintiff in the class action lawsuit [1][7]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [7]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its significant recoveries in securities fraud litigation [8].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud that negatively impacted investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products [2]. - The company is said to be unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2]. - Positive statements made by the defendants regarding the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Altimmune, Inc. due to alleged securities fraud affecting investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, where the company failed to achieve statistical significance in the primary endpoint of fibrosis reduction [2] - The stock price of Altimmune plummeted by 53.2%, from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, following the announcement of the trial results [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]